Revvity, Inc. (RVTY) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strategic partnerships, AI-driven product development, and raised EPS guidance, which are positive indicators. The Q&A section reveals cautious optimism in biotech funding and consistent order trends. Despite a conservative approach to Diagnostics and China IDX, strong free cash flow conversion and a robust software pipeline suggest potential growth. The company's proactive strategies and positive guidance adjustments outweigh concerns, indicating a likely stock price increase.
Key Financial Performance
Adjusted EPS (Earnings Per Share) $5.06 for the year, representing a 3% growth year-over-year. The increase was attributed to strong fourth-quarter performance, overcoming challenges such as changes in NIH funding, evolving tariffs, and foreign exchange movements.
Organic Growth 3% for the year, within the original guidance range. Despite challenges like the U.S. government shutdown and DRG-related volume shifts in China, the company achieved this growth due to resilience and operational agility.
Diagnostics Segment Organic Growth 7% in Q4 and 4% for the year. Growth was driven by better-than-expected performance in reproductive health and immunodiagnostics, despite DRG-related volume pressures in China.
Life Sciences Segment Organic Growth Flat year-over-year in Q4 and 2% for the year. Growth was supported by low single-digit increases from pharma customers, offset by low single-digit declines in academic and government sales.
Adjusted Operating Margins 29.7% in Q4, down 60 basis points year-over-year, and 27.1% for the year, down 120 basis points year-over-year. The decline was due to tariffs, FX, and lower volume leverage, partially offset by cost containment initiatives.
Share Repurchase Activity Over $800 million worth of shares repurchased in 2025, reducing the share count by 8.5 million shares. This activity reflects confidence in the company's transformation and long-term potential.
Free Cash Flow $515 million for the year, equating to 87% conversion of adjusted net income. This strong cash flow supported share repurchases and other capital deployment activities.
Revenue $772 million in Q4, representing 4% organic growth. For the full year, revenue was $2.86 billion, with 3% organic growth and a 1% FX tailwind.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Signals Xynthetica AI platform: Introduced as a service platform to integrate AI and ML models into pharma preclinical R&D workflows, enabling faster drug development.
ACD/Labs acquisition: Acquired and integrated into the Signals business, expected to contribute $20 million in revenue for 2026.
Geographic performance: Double-digit growth in Europe, flat performance in Americas and APAC for Q4 2025.
Diagnostics segment: 7% organic growth in Q4 2025, driven by reproductive health and immunodiagnostics.
Cost efficiency initiatives: Programs include footprint consolidations, commercial and operational integrations, and supply chain synergies, expected to complete by mid-2026.
Share repurchase: Over $800 million worth of shares repurchased in 2025, reducing share count by 8.5 million.
Capital deployment: Focused on balanced mix of buybacks, M&A, and internal investments, with $1.5 billion spent on share repurchases since mid-2023.
Collaboration with Lilly TuneLab: Partnership to integrate AI models into drug development, leveraging $1 billion of R&D investment by Lilly.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Changes in NIH funding: Uncertainty in NIH funding could impact the company's revenue and growth, particularly in the Life Sciences segment.
Evolving tariffs: Tariffs have pressured operating margins and could continue to impact costs and profitability.
Pharma policy uncertainty: Uncertainty in pharmaceutical policies could affect customer demand and market dynamics.
Extended U.S. government shutdown: The shutdown created modest headwinds for sales from academic and government customers, impacting the Life Sciences segment.
Foreign exchange movements: FX fluctuations have created headwinds for revenue and operating margins, particularly in the Diagnostics segment.
Shifts in DRG-related volumes in China: Declines in DRG-related volumes in China have negatively impacted the Diagnostics business and are expected to continue until mid-2026.
Fluid end market and policy environment: The dynamic and uncertain market and policy environment could impact customer demand and strategic execution.
Tariff impacts and cost efficiency initiatives: Tariffs and the need for cost efficiency measures have pressured margins, requiring ongoing operational adjustments.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Organic Growth Outlook: Reiterating 2% to 3% organic growth for 2026, assuming recent end market trends continue. Potential for updates if customer demand recovers more than anticipated.
Revenue Projections: Total expected revenue for 2026 is projected to be in the range of $2.96 billion to $2.99 billion, including a 1% FX tailwind and contributions from the ACD/Labs acquisition.
Adjusted Operating Margins: Expected to be 28% for 2026, up from 27.1% in 2025, with potential for additional leverage and margin expansion if organic revenue growth exceeds expectations.
Adjusted Earnings Per Share (EPS): Projected to be in the range of $5.35 to $5.45 for 2026, representing high single-digit growth.
Cost Efficiency Initiatives: Programs including footprint consolidations, commercial and operational integrations, and supply chain synergies are expected to be fully implemented by the end of Q2 2026, contributing to margin improvements.
Signals Xynthetica AI Platform: Launch of AI models as a service platform, Signals Xynthetica, expected to accelerate drug development timelines and enhance preclinical R&D workflows.
ACD/Labs Acquisition: Integration into the Signals business is underway, with expected revenue contribution of over $20 million in 2026, adding approximately 75 basis points to overall revenue growth.
Capital Deployment: Continued focus on balanced and disciplined capital deployment, including share buybacks, M&A, and internal investments.
Tax Rate: Adjusted tax rate for 2026 is expected to be 18%, up from 14.5% in 2025.
First Quarter 2026 Guidance: Organic growth expected to align with full-year guidance of 2% to 3%, with a 3% FX tailwind. Adjusted operating margins projected at 23% for Q1, improving throughout the year.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase in 2025: Revvity repurchased over $800 million worth of shares, reducing the share count by 8.5 million shares.
Total Share Repurchase since 2023: Since becoming Revvity in mid-2023, the company has repurchased over $1.5 billion worth of shares, representing nearly 15 million repurchased shares or about 12% of the total share count at the time.
Capital Deployment Strategy: The robust repurchase activity during a period of elevated end market uncertainty demonstrates confidence in the company's transformation and medium- to longer-term potential. The company plans to remain opportunistic and disciplined in evaluating capital deployment opportunities.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide more color on the 2% to 3% organic growth guidance and potential upside for 2026?
A:The 2% to 3% organic growth guidance is consistent with the framework provided in September. Positive signs in end markets, such as improvements in the biotech funding environment and M&A activity, suggest potential upside. However, the guidance assumes no material benefit from new software launches or significant changes in preclinical markets. Diagnostics assumptions are more conservative, particularly for newborn screening and China IDX. Potential EPS upside could come from margin expansion and tax planning initiatives.
Q:What is driving strength in instruments and reagents in the Life Sciences segment?
A:Strength in instruments and reagents is driven by continued momentum in the preclinical market and positive indicators in pharma biotech. The company has been taking market share in the preclinical reagents business and expects to continue executing on this trend.
Q:Can you provide an update on the timing and uptake trajectory for new software products?
A:The company is launching new products like BioDesign, Xynthetica, and LabGistics, which are expected to drive growth in the Signals business. While no material benefit is expected in 2026, the company anticipates these products will accelerate growth over time, potentially achieving a 15% organic growth rate in the software segment.
Q:How is biotech funding improvement impacting the Life Sciences business?
A:Biotech funding improvements, along with increased clarity in policy and regulatory environments, are contributing to cautious optimism. While there are early signs of recovery, the company is waiting for sustained trends before making a call on a durable uptick.
Q:How are Life Sciences and Diagnostics expected to perform relative to the 2% to 3% corporate growth guidance?
A:Both Life Sciences and Diagnostics are expected to grow in the low single digits. Within Life Sciences, reagents are expected to grow in the low single digits, while instrumentation is expected to be flat. Diagnostics growth is driven by mid-single-digit growth in reproductive health and low single-digit growth in immunodiagnostics, with high single-digit growth expected outside of China.
Q:What is the company's approach to M&A, and is a merger of equals on the table?
A:The company is focused on strategic additions in software and life sciences reagents. While a merger of equals is not ruled out, any potential deal must meet strict financial and strategic criteria. Currently, no compelling targets have been identified.
Q:What trends were observed in the pharma biotech segment within Life Sciences Solutions?
A:The company observed cautious optimism and consistent order trends, with no significant budget flush. Improved clarity and confidence in policy and regulatory environments are enabling better planning by pharma biotech customers.
Q:What drove the better-than-expected performance in Diagnostics in Q4, and is it sustainable?
A:Diagnostics outperformed expectations due to strength in newborn screening and immunodiagnostics. While the company has taken a more conservative approach for 2026, there is potential upside if these trends continue.
Q:What is the outlook for China IDX in 2026?
A:China IDX is expected to represent less than 5% of total company revenue in 2026. The company has taken a more prudent assumption, expecting slight declines in the second half of the year, with no fundamental changes in market conditions.
Q:What are the moving parts for margins in 2026, especially in Q1?
A:Margins in Q1 are expected to be lighter than normal due to the extra week of costs and ongoing cost-saving initiatives, which will be fully executed by the end of Q2. Margins are expected to improve in the second half of the year.
Q:How is the company calibrating software launch expectations in a challenging market?
A:The company is leveraging its installed base and customer demand to drive adoption of new software products. These launches are expected to gain traction over time, with a focus on upselling within the existing Signals suite.
Q:What is the economic opportunity for the AI drug discovery offering in software?
A:The AI drug discovery offering, Xynthetica, aims to accelerate drug discovery by integrating in silico modeling with wet lab processes. The platform provides a federated model for AI modules, enabling productivity and efficiency gains. The company is optimistic about its long-term potential, as evidenced by its partnership with Lilly.
Q:What is the outlook for free cash flow conversion in 2026?
A:The company expects free cash flow conversion to remain strong, targeting 85% or greater for 2026. This is supported by working capital initiatives, a higher recurring revenue mix, and company-wide cash flow targets.
Q:How does the extra week in Q1 impact organic growth and margins?
A:The extra week in Q1 adds about 100 basis points to organic growth but is a margin headwind due to additional labor costs. This results in a $0.06 EPS headwind for the quarter.
Q:What are the competitive dynamics in the reagents business?
A:The company has not observed any margin dilution or significant competitive pressures in the reagents business. It continues to perform well and gain market share.
Q:What is the outlook for the instruments business in 2026?
A:The instruments business is expected to be flat in 2026, with high-content screening showing strong momentum. Other segments are expected to remain stable, with no significant changes in demand.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct answer to the question about the potential for a merger of equals, stating only that any deal must meet strict financial and strategic criteria. Additionally, while discussing the AI drug discovery offering, the response lacked specific numerical details about the economic opportunity, focusing instead on qualitative benefits.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ACD Labs
ACD Signals
ACD acquisition
ACD basis
AI ML
AI model
AI repository
China challenge
DRG volume
Diagnostics Life
FX ACD
Labs process
Lilly TuneLab
NIH funding
RD
Singh
TuneLab AI
collaboration Lilly
drug development
employee
exchange
government shutdown
insight
introduction
loop
momentum
note
pharma company
platform Signals
policy
potential
progress
repurchase activity
scientist
spite
uncertainty
workflow
RVTY Transcript
Revvity, Inc. (RVTY) Q4 2025 Earnings Call Transcript
Positive2-2
The earnings call highlights strategic partnerships, AI-driven product development, and raised EPS guidance, which are positive indicators. The Q&A section reveals cautious optimism in biotech funding and consistent order trends. Despite a conservative approach to Diagnostics and China IDX, strong free cash flow conversion and a robust software pipeline suggest potential growth. The company's proactive strategies and positive guidance adjustments outweigh concerns, indicating a likely stock price increase.
Revvity, Inc. (RVTY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-13
Revvity, Inc. (RVTY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Neutral12-2
Revvity, Inc. (RVTY) Presents at Jefferies London Healthcare Conference 2025 Transcript
Neutral11-18
RVTY Slides
RVTY Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
